ATRA - Atara Biotherapeutics Inc

5.17
0.170   3.288%

Share volume: 404,703
Last Updated: 03-06-2026
Pharmaceutical Products/Biological Products, Except Diagnostic Substances: 0.19%

PREVIOUS CLOSE
CHG
CHG%
$5.00
0.17
0.03%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
45%
Profitability 60%
Dept financing 43%
Liquidity 52%
Performance 30%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
5.30%
1 Month
3.82%
3 Months
-65.72%
6 Months
-57.55%
1 Year
-25.07%
2 Year
642.50%
Key data
Stock price
$5.17
P/E Ratio 
4.30
DAY RANGE
$4.70 - $5.36
EPS 
$1.71
52 WEEK RANGE
$3.92 - $19.14
52 WEEK CHANGE
-$16.07
MARKET CAP 
100.640 M
YIELD 
N/A
SHARES OUTSTANDING 
7.210 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
05-08-2025
BETA 
-0.62
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$284,968
AVERAGE 30 VOLUME 
$160,661
Company detail
CEO: Pascal Touchon
Region: US
Website: atarabio.com
Employees: 330
IPO year: 2014
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Biological Products, Except Diagnostic Substances
Sector: Manufacturing

Atara Biotherapeutics, Inc. develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease. The company was incorporated in 2012 and is headquartered in South San Francisco, California.

Recent news